## Diagnosis and Clinical Context This patient has **systolic heart failure with reduced ejection fraction (HFrEF)** (LVEF 35%) with clinical signs of pulmonary and systemic congestion (orthopnea, PND, elevated JVP, bilateral basal crackles). The underlying etiology is likely **hypertensive cardiomyopathy** — LVH with strain pattern progressing to systolic dysfunction. ## Why Option B Is Correct **Lisinopril 2.5 mg daily + carvedilol 3.125 mg BD + increase amlodipine to 10 mg** represents initiation of **Guideline-Directed Medical Therapy (GDMT)** for HFrEF: - **ACE inhibitor (lisinopril):** First-line agent for all HFrEF (LVEF ≤40%). Reduces afterload, prevents adverse ventricular remodeling, and reduces all-cause mortality (CONSENSUS, SOLVD trials). Starting dose is deliberately low (2.5 mg) to minimize hypotension and hyperkalemia. - **Beta-blocker (carvedilol):** One of three mortality-reducing beta-blockers in HFrEF (carvedilol, metoprolol succinate, bisoprolol). Initiated at low dose (3.125 mg BD) once the patient is not acutely decompensated. Reduces sudden cardiac death and all-cause mortality (COPERNICUS trial). - **Amlodipine increase:** Appropriate for ongoing hypertension control. Amlodipine is the only calcium channel blocker considered safe in HFrEF (PRAISE trial) and does not worsen outcomes. **High-Yield:** The **GDMT triad** in HFrEF is: ACE-I/ARB → Beta-blocker → MRA (spironolactone/eplerenone if LVEF ≤35%). Diuretics are added for symptom relief but do NOT reduce mortality. ## Why Other Options Are Incorrect - **Option A (Cardiac catheterization):** Not indicated as the immediate next step. Catheterization is reserved for suspected ACS, angina, or when ischemic etiology needs to be excluded before initiating therapy. This patient's presentation is consistent with hypertensive cardiomyopathy without features of acute ischemia. - **Option C (Spironolactone monotherapy):** MRA is indicated as an *add-on* agent in HFrEF (LVEF ≤35%), not as monotherapy. Initiating spironolactone without ACE-I and beta-blocker violates guideline sequencing and misses the two most mortality-reducing drug classes. - **Option D (Furosemide + cardiology referral only):** Loop diuretics address congestion and improve symptoms but have **no mortality benefit** in HFrEF. Starting furosemide alone without GDMT (ACE-I + beta-blocker) is inadequate management. Cardiology referral is appropriate but should not delay initiation of evidence-based therapy. ## Clinical Pearl In a **stable, non-acutely decompensated** HFrEF patient (as in this vignette — chronic 3-month history, not in flash pulmonary edema), GDMT should be initiated promptly. If significant fluid overload were present, a loop diuretic would be added *alongside* GDMT, not instead of it. **Key Point:** Uptitration of ACE-I and beta-blocker to target doses (lisinopril 10–40 mg, carvedilol 25–50 mg BD) occurs over weeks to months as tolerated. [cite: Harrison's Principles of Internal Medicine, 21e, Ch. 252 (Heart Failure); ACC/AHA 2022 Heart Failure Guidelines; KD Tripathi Essentials of Medical Pharmacology, 8e]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.